The Cambridge Lighthouse Laboratory, established by AstraZeneca, the University of Cambridge and GlaxoSmithKline, and subsequently partnering with Charles River Laboratories, was part of NHS Test and Trace’s network of Lighthouse laboratories which provides population-wide diagnostic testing.
BiologIC, AstraZeneca and Electrolux Professional combined bioscience and thermal expertise to rapidly implement an innovative, production-ready heat inactivation solution in this safety-critical process. Rigorous validation demonstrated inactivation of the COVID-19 virus whilst maintaining the accuracy of diagnostic testing. The parties have now successfully implemented this solution, using Skyline Ovens from Electrolux Professional.
Richard Vellacott, CEO of BiologIC Technologies, said: "Combined with vaccines, diagnostic testing will be critical to re-mobilising our local, national and international communities, particularly as new strains of COVID-19 continue to evolve. We were pleased to identify, validate and support implementation of this solution to greatly enhance the safety, cost-effectiveness and scalability of COVID-19 diagnostic testing."
Steve Rees, VP Discovery Biology, R&D, AstraZeneca, said: “Our collaborative innovative solution enables virus inactivation upon receipt at the laboratory allowing work on the open bench, which simplifies the workflow, reduces the risk of employee exposure to live virus, and facilitates future innovations around automation of the sample unpackaging process.”
Alberto Zanata, CEO of Electrolux Professional, added: “With the advanced technology of the SkyLine combi oven, we support yet another milestone in fighting the pandemic that is affecting people and businesses around the world. We are very proud to play a role in safeguarding the process of handling the COVID-19 samples, to protect all people involved in testing.
Image: BiologIC Technologies helps implement high-throughput heat inactivation of patient samples at Cambridge UK COVID-19 Test Centre. (Photo: Business Wire)